Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. [electronic resource]
Producer: 20131212Description: 6013-23 p. digitalISSN:- 1538-7445
- Animals
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antineoplastic Agents -- pharmacology
- Breast Neoplasms -- metabolism
- Cell Proliferation -- drug effects
- Class I Phosphatidylinositol 3-Kinases -- antagonists & inhibitors
- Female
- Humans
- Immunoblotting
- Immunoprecipitation
- Lapatinib
- Mice
- Phosphorylation -- drug effects
- Protein Multimerization -- drug effects
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- Receptor, ErbB-3 -- antagonists & inhibitors
- Signal Transduction
- Survival Rate
- Trastuzumab
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.